Melissa Loseke, DO - Wellness and Longevity
- PRP Therapy
- Ozone Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
- Peptide Therapy
Omaha, NE
Omaha has a stable Midwestern healthcare hub anchored by Nebraska Medicine and full NP practice authority, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across West Omaha, Dundee, and Midtown range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Nebraska Medicine, CHI Health, and Methodist network. The scene here skews toward NP-run and DO-run clinics offering peptides alongside hormone optimization. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Omaha clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The Nebraska Board of Pharmacy, operating under the Department of Health and Human Services, inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Nebraska must hold a current non-resident pharmacy license. Disciplinary actions are published through the DHHS licensure system.